Long-term experience with 181 patients who received transperineal I-125 implants for prostate cancer: Efficacy and urinary toxicity
| Autor: | Daniel Shahar, Tanya Mashiac, Eliahu Gez, David Kakiashvili, Abraham Kuten, Rachel Bar Deroma, Simon Meretyck, Valeriya Semenisty, Joshua Genesin |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Urinary system Urology medicine.disease Radiation therapy Prostate cancer medicine.anatomical_structure Urethra Oncology Prostate medicine Hormonal therapy Radiology Nuclear Medicine and imaging Implant business Prostate brachytherapy |
| Zdroj: | Journal of Radiotherapy in Practice. 11:16-22 |
| ISSN: | 1467-1131 1460-3969 |
| DOI: | 10.1017/s1460396910000531 |
| Popis: | Background: In low-risk prostate cancer, the target volume for radiotherapy is the prostate gland only and prostate brachytherapy with an I-125 implant provides the most conformal radiotherapy.Methods: Patients underwent a pre-implant prostate volume study from which a treatment plan was developed 2 weeks prior to implant. A dosimetric study was performed 1 month following the implant. The prescription dose was 145 Gy with the 95% isodose line covering the entire target volume. The maximal dose to the urethra was less than 210 Gy. Follow-up included serum PSA and IPSS evaluation every 3 months during the first year and then every 6 months beginning in the second year.Results: During December 2000–March 2009, 181 patients with early prostate cancer underwent I-125 implant. The median post-implant PSA value of the entire cohort was 0.7 ng/ml. No patient developed clinical failure. In the follow-up, nine patients had biochemical failure according to the RTOG-ASTRO Phoenix definition (Nadir + 2.0 ng/ml). Of these, one patient refused hormonal therapy desiring to preserve sexual potency, and eight patients received hormonal therapy with a decreased serum PSA to 0.0 ng/ml. The treatment side effects were primarily urinary disturbances.Conclusion: An I-125 implant is an effective and well-tolerated treatment and should be recommended for patients with low-risk prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|